Randomised, single-centre, placebo controlled study on nightly use of selective histamine antagonists as a novel and tailored drug treatment option in narcolepsy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00014960

Enrollment

Registered

2018-08-13

Start date

2020-10-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G47.4

Interventions

Group 1: 12 patients with narcolepsy, which will get Doxepin (Sinquan®) 10mg capsules once a day orally for 8 weeks. All patients will fill out every 2 weeks the questionnaires (FSS, ESS, PSQI, HADS)

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Narcolepsy patients typ 1

Exclusion criteria

Exclusion criteria: 1. Age <18 years 2. Non cooperating persons 3. Consumption of illicit drugs 4. Women who are pregnant or breast feeding 5. Contraindications to treatment with Doxepin 6. Severe depression

Design outcomes

Primary

Measure	Time frame
Improvements of the actigraphic and polysomnographic measures of sleep consolidation, cataplexy diary and mean sleep latency on the Maintenance of Wakefulness Test. Evaluation of the parameters before treatment start and after 8 weeks.	—

Countries

Switzerland

Contacts

Public ContactPhilipp Valko

UniversitätsSpital ZürichKlinik für Neurologie

philipp.valko@usz.ch0041 255 1111

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026